Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemoth
about
Multimodal management of muscle-invasive bladder cancerLong-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?Systemic therapy in bladder cancerTrimodality therapy for bladder preservation in the elderly population with invasive bladder cancer.Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survivalLong-term urinary adverse effects of pelvic radiotherapy.External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer.Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder.Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapyDual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapyTrimodality therapy in bladder cancer: who, what, and when?The role of PD-L1 in the radiation response and clinical outcome for bladder cancer.Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy.Multimodal therapies for muscle-invasive urothelial carcinoma of the bladderRadio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control.Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients.Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancerThe Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder CancerTransurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome.Trimodality treatment for bladder cancer: does modern radiotherapy improve the end results?Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen.Current management of muscle-invasive bladder cancer.Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.Primary bladder preservation treatment for urothelial bladder cancer.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.Improving Systemic Chemotherapy for Bladder Cancer.Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysisMuscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer.Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection.Update on chemotherapy in the treatment of urothelial carcinoma
P2860
Q27011624-0E9B9652-C1D7-4877-B089-4585B2DA26D6Q30277868-DF5F9FBA-20C2-418D-A5FF-C758814070DCQ33578560-721720E2-3DB0-4556-9D60-0D77C9F4F848Q33578564-AC73B0FA-5999-4C51-BE60-9E8381022629Q34004008-B1155DCA-C03E-4AE7-B638-A5552DB25694Q34551018-6A9C08DE-4950-4FB8-9F5B-C9976C2F71A4Q34669655-251BCA61-A794-40EB-B360-347B7EE65420Q34786513-0BDE3266-E023-4934-9BA1-498B3A2AD604Q34990822-1CAD34E4-587F-445F-A0C5-58A09B59D671Q35125750-ED767F45-2BA5-4E9D-BEBB-EA20EF5E2AFEQ35174486-080BE9E4-3937-4E08-B18B-F7C829AFB698Q35495280-FDE25C73-E437-4D4D-8F84-1E4E7A0F8506Q35667815-3608A42D-2042-4DA6-825E-E54EC203494EQ35733590-876A2656-9075-4549-AA81-7520B0411C55Q36500650-39C85916-5BD2-42D3-9884-CA087EE960F5Q36962466-341B4BD4-52B8-4A0A-8CCC-A7DB410516BBQ36973553-6ECE6DFA-A2CF-49A8-85D3-47738815D9DBQ37135495-31B55484-908E-43F8-ADF4-D95AA144C6E2Q37325066-A3CF4AF6-567A-4372-A0F8-04A1AFED57D0Q37404685-C0C59AE2-E002-4827-8C00-9C1D059EF96CQ37430823-CC971C6E-099A-4B3F-B54C-2A3047DE1B46Q37530349-84DF9374-08BF-417F-9E75-21AB48D90C61Q37601953-77FABAAE-5E93-4A16-9232-94F67BCCDB05Q37812608-C1C7F58B-FFCA-419C-99C4-614635858E33Q37955283-AA76BEC9-999A-4B1E-AA61-F82570587C93Q37962658-35AAFC86-F2DE-4A21-A400-9F632052DFC0Q37992672-731F2682-5A44-4FB4-8005-B70A6A9EB955Q38076093-E6B91551-85F3-4199-9618-69BF1C877CE1Q38118058-702B6D2B-713A-4B10-BF05-F75A33974D27Q38255032-F2D43EF8-28E6-4398-84A3-F8898F07B262Q38615547-C9F4D087-67A1-42AF-A86C-7E412B34030BQ38777610-A59EFC17-546F-49DD-BA16-C0CE512F7CC2Q41998977-66B61AD5-C90E-4449-9CD4-583603BE25BAQ43084153-261B6171-3E46-4FFD-80FB-AC9C6568208DQ47134723-28ABC106-4360-4063-8C0E-6658B23628A0Q51748560-2FCB55F1-CD97-4264-9D86-FE5606FCE421Q58694390-6BB40647-A1E9-45D0-AE9C-2B211ABD986D
P2860
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemoth
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@en
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@nl
type
label
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@en
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@nl
prefLabel
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@en
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@nl
P2093
P1433
P1476
Phase I-II RTOG study (99-06) ...... ystectomy and adjuvant chemoth
@en
P2093
Anthony L Zietman
Donald S Kaufman
H James Wallace
Howard M Sandler
Kathryn A Winter
Leonard M Toonkel
Niall M Heney
Simon Tanguay
William U Shipley
P304
P356
10.1016/J.UROLOGY.2008.09.036
P407
P577
2008-12-18T00:00:00Z